Physician profile
Veronica Manka
NPI 1235143033
$1,310.73
in general payments reported to CMS, 2019-2025
22 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $162 · 2021: $154 · 2022: $69.03 · 2023: $213 · 2024: $319 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $178.90 | 2022-2024 | Azstarys |
| Sanofi-Aventis U.S. LLC | $168.00 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $157.46 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $135.02 | 2019-2021 | |
| Sanofi Pasteur INC. | $74.45 | 2019-2024 | |
| Seqirus USA INC | $72.05 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $62.96 | 2020 | |
| Pfizer INC. | $55.56 | 2025 | |
| Supernus Pharmaceuticals, INC. | $53.65 | 2021-2023 | Qelbree |
| Adlon Therapeutics L.P. | $44.08 | 2020-2021 | |
| Kaleo, INC. | $42.46 | 2021 | |
| Merck Sharp & Dohme LLC | $41.84 | 2019-2025 | Enflonsia, Vaxneuvance, Gardasil 9 |
| Collegium Pharmaceutical, INC. | $35.76 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $34.72 | 2020-2023 | Pediarix, Menveo, Bexsero |
| Vertical Pharmaceuticals, LLC | $29.38 | 2025 | Relexxii |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $26.19 | 2024 | Ycanth |
| Genzyme Corporation | $23.26 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.19 | 2019 | |
| Novo Nordisk INC | $16.46 | 2025 | Wegovy |
| Tris Pharma INC | $15.66 | 2021 | |
| Shire North American Group INC | $13.40 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Manka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.